Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $8,534,014.58 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 184,639 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the transaction, the director directly owned 2,671,822 shares in the company, valued at $123,491,612.84. This trade represents a 6.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Stock Up 5.3%

Shares of SION stock opened at $43.12 on Thursday. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -22.34 and a beta of 1.35. The stock has a fifty day moving average of $39.11 and a 200 day moving average of $39.51. Sionna Therapeutics, Inc. has a 52 week low of $11.77 and a 52 week high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Equities research analysts anticipate that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Institutional Trading of Sionna Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. TD Asset Management Inc boosted its holdings in Sionna Therapeutics by 74.3% in the third quarter. TD Asset Management Inc now owns 87,082 shares of the company’s stock worth $2,561,000 after acquiring an additional 37,116 shares in the last quarter. Jennison Associates LLC increased its stake in Sionna Therapeutics by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after purchasing an additional 117,903 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Sionna Therapeutics in the third quarter worth about $147,000. Artia Global Partners LP purchased a new position in Sionna Therapeutics in the fourth quarter worth about $4,926,000. Finally, Eventide Asset Management LLC bought a new position in shares of Sionna Therapeutics in the fourth quarter worth approximately $26,290,000.

Key Stories Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Sionna Therapeutics and kept a $58 price target, implying meaningful upside from recent trading levels and reinforcing optimism around the company’s clinical pipeline. Article Title
• Positive Sentiment: Sionna Therapeutics said management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 20, which can give investors a fresh update on the company’s cystic fibrosis programs and keep attention on the story. Article Title
• Neutral Sentiment: In its first-quarter update, the company said enrollment is complete in the PreciSION CF Phase 2a trial for SION-719 and that topline data is expected in summer 2026, while the SION-451 Phase 1 study is also on track. It also reported a strong cash balance of about $289.9 million, supporting operations into 2028. Article Title
• Negative Sentiment: Sionna reported a first-quarter loss of $0.60 per share, wider than the expected $0.52 loss, which may weigh on sentiment even though the company remains pre-revenue and focused on clinical development. Article Title
• Negative Sentiment: Director OrbiMed Advisors and director Peter A. Thompson disclosed several large share sales in recent days. The transactions were made under pre-arranged 10b5-1 plans, but the size of the selling can still pressure investor sentiment. Article Title

Wall Street Analyst Weigh In

SION has been the subject of several research analyst reports. Wedbush initiated coverage on shares of Sionna Therapeutics in a report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price objective for the company. Citizens Jmp initiated coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 target price for the company. BTIG Research restated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday, May 8th. Finally, Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $53.00.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.